ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Muscle Biology"

  • Abstract Number: 2073 • ACR Convergence 2025

    Cell-free DNA as a Potential Marker of Muscle Involvement and Treatment Response in Myositis

    Sabína Oreská1, Kristina Svobodová1, Lucia Vernerová1, Dana Dlouhá2, Hana Wunsch1, Karel Pavelka1, Jiri Vencovsky3, Ladislav Šenolt4, Michal Vrablik5, Jaroslav Alois Hubáček2 and Michal Tomcik1, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Experimental Medicine Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 3Institute of Rheumatology, Praha 8, Czech Republic, 4Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 53rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are characterized by inflammatory muscle injury. Circulating cell-free DNA (cfDNA), including nuclear (cfnDNA) and mitochondrial (cfmtDNA) DNA, has been shown…
  • Abstract Number: 1826 • ACR Convergence 2025

    Single Nuclei Multiome of JDM Muscle Biopsies Reveals Novel Upregulation of Inflammatory and Vascular Pathways

    Shannon O'Connor, Casey Swoboda, Matthew Weirauch, Alexander Zygmunt, Douglas Millay and Leah Kottyan, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Juvenile dermatomyositis (JDM) is a multisystem vasculopathy and inflammatory myopathy characterized by proximal muscle weakness, distinct rash, and risk of long-term complications such as…
  • Abstract Number: 1211 • ACR Convergence 2025

    Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis

    Kristina Svobodová1, Sabína Oreská1, Lucia Vernerová2, Dana Dlouhá3, Hana Wunsch2, Karel Pavelka2, Jiri Vencovsky4, Ladislav Šenolt5, Michal Vrablik6, Jaroslav Alois Hubáček3 and Michal Tomcik2, 1Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 3Experimental Medicine Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic, 4Institute of Rheumatology, Praha 8, Czech Republic, 5Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 63rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) involve muscle inflammation. MicroRNAs (miRNAs), such as miR-133a-3p and miR-1-3p, play a key role in gene regulation and muscle repair.…
  • Abstract Number: 1204 • ACR Convergence 2025

    Validity and reliability of a new ultrasound-based semiquantitative echogenicity grading scale for myositis.

    Takeshi Yoshida1, Didem Saygin2 and Jemima Albayda3, 1Johns Hopkins Hospital, Baltimore, MD, 2Rush University Medical Center, Chicago, IL, 3Johns Hopkins University, Baltimore, MD

    Background/Purpose: The Heckmatt grading scale has been widely used as a semiquantitative assessment method for grading muscle echo intensity (EI) on ultrasound; however, this was…
  • Abstract Number: 0999 • ACR Convergence 2025

    Myositis Induced by Histidyl-Transfer tRNA Synthetase is Exacerbated by Membranopathy and Suppressed by Regulatory T Cells

    Samantha Coss1, Nicholas Young2, Shane Bruckner3, Braden Zeno4, Gianni Giarrano5, Hannah Bulgart6, Paula Clemens7, Jisna Paul2, Chester V. Oddis8, noah weisleder9, Dana Ascherman8 and Wael Jarjour10, 1Nationwide Children's Hospital, Columbus, OH, 2Division of Rheumatology and Immunology, Department of Internal Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, Columbus, OH, 3OSU, Columbus, OH, 4Ohio State University, upper arlington, OH, 5Division of Rheumatology, Nationwide Children's Hospital, Columbus, OH, 6Department of Molecular and Cellular Biochemistry, University of Kentucky College of Medicine, Lexington, KY, 7Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA, 8University of Pittsburgh, Pittsburgh, PA, 9University of Kentucky, Lexington, KY, 10The Ohio State University, Columbus, OH

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of autoimmune disorders targeting muscle as well as extra-muscular organs. Among the most common autoantibodies associated…
  • Abstract Number: 0280 • ACR Convergence 2025

    Sera from dermatomyositis patients induce muscle weakness via activation of type I interferon (IFN) receptors.

    Suchada Kaewin1, Cecilia Leijding2, Kristofer Andreasson2, Helene Alexanderson3, Stefano Gastaldello1, Ingrid Lundberg2 and Daniel C. Andersson2, 1Karolinska Institutet, inst fysiologi och farmakologi, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, Sweden, 3Karolinska University Hospital, Stockholm, Sweden

    Background/Purpose: Dermatomyositis (DM) is a major subtype of idiopathic inflammatory myopathies (IIMs) and characterized by muscle weakness, systemic inflammation and cutaneous lesions. Expression of type…
  • Abstract Number: 0026 • ACR Convergence 2025

    Spatial Proteomic-based Phenotyping of Muscle Stem Cells and their Niches in Myositis

    Bilgesu Safak Tümerdem1, Yi-Nan Li2, Tim Filla3, Rolf Schröder4, Anna Brunn5, Alexandru Micu6, Ayla Nadja Stuetz1, Laura-Marie Lahu6, Aleix Rius Rigau7, Christina Bergmann8, Alexandru-Emil Matei9, Jörg Distler10 and Andrea-Hermina Györfi11, 1Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Nordrhein-Westfalen, Germany, 2University Hospital of Düsseldorf, Düsseldorf, Germany, 3Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University., Düsseldorf, Germany, 4Institute of Neuropathology, Friedrich-Alexander University Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 5Institute of Neuropathology, Heinrich-Heine University, University Hospital of Düsseldorf, Düsseldorf, Germany, 6Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University, Düsseldorf, Germany, 7Department of Internal Medicine 3, Rheumatology and Clinical Immunology, Friedrich-Alexander-University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen. Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, 8Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, 9Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, and Fraunhofer Cluster of Excellence for Immune Mediated Diseases CIMD, Frankfurt am Main, Germany, Düsseldorf, Germany, 10University Hospital Duesseldorf and HHU, Duesseldorf, Germany, 11Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University., Düsseldorf, Germany

    Background/Purpose: Immune-mediated inflammatory myopathies (IIMs) are a heterogeneous group of diseases characterized by chronic inflammation, damage and impaired regeneration of the skeletal muscle leading to…
  • Abstract Number: 2085 • ACR Convergence 2024

    The Effects of Pioglitazone on Metabolic Dysregulation in Inclusion Body Myositis: An Open-Label Pilot Study

    Brittany Adler1, Michael Bene1, Cissy Zhang2, Julie Paik1, Christopher Mecoli1, Thomas Lloyd3, Eleni Tiniakou4, Erika Darrah1, Lisa Christopher-Stine1, Albert Mears1, Megan McGowan1, Ruben Pagkatipunan1, Anne Le2 and Jemima Albayda5, 1Johns Hopkins University, Baltimore, MD, 2Gigantest, Baltimore, MD, 3Baylor College of Medicine, Houston, TX, 4Johns Hopkins University, Lutherville Timonium, MD, 5Johns Hopkins School of Medicine, Baltimore, MD

    Background/Purpose: Inclusion body myositis (IBM) is a progressive muscle disease for which there is no effective treatment. Mitochondrial dysregulation is a pathologic hallmark of IBM.…
  • Abstract Number: 2669 • ACR Convergence 2024

    Dysferlin Autoantibodies Compromise Sarcolemmal Repair Capacity and Contribute to the Pathogenesis of Idiopathic Immune Myopathies

    Hannah Bulgart1, Kassidy Banford2, Shane Bruckner3, Kevin McElhanon2, Nicholas Young1, Brian Paleo2, Eric Beck2, Rohit Aggarwal4, Chester Oddis5, Braden Zeno6, Wael Jarjour7 and Noah Weisleder3, 1The Ohio State University Wexner Medical Center, Columbus, OH, 2The Ohio State University, Columbus, 3Ohio State University, Columbus, OH, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 6Ohio State University, upper arlington, OH, 7The Ohio State University, Columbus, OH

    Background/Purpose: Idiopathic immune myopathies (IIMs) are a group of autoimmune diseases that produce chronic inflammation and degeneration of skeletal muscle structure and function. One process…
  • Abstract Number: 2670 • ACR Convergence 2024

    Sera from Patients with Idiopathic Inflammatory Myopathy Induces Muscle Weakness, Mitochondrial Dysfunction and Induction of Cytokines in Isolated Skeletal Muscle

    Cecilia Leijding1, Suchada Kaewin2, Kristofer Andreasson1, Tomas Schiffer1, Angeles Galindo-Feria3, Begum Horuluoglu1, Mattias Carlstrom1, Stefano Gastaldello1, Helene Alexanderson4, Ingrid Lundberg5 and Daniel Andersson6, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska Institutet, Stockholm, 3Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden, 4Karolinska University Hospital, Stockholm, Sweden, 5Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden, 6Karolinska Institutet, Solna, Sweden

    Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of systemic autoimmune inflammatory muscle disorders characterized by symmetrical skeletal muscle weakness and accelerated fatigue. Although signs…
  • Abstract Number: 0163 • ACR Convergence 2024

    Modification of 2017 EULAR/ACR Myositis Classification Criteria for Dermatomyositis, Clinically Amyopathic Dermatomyositis, and Immune-mediated Necrotizing Myopathy

    Ching Chung1, Yusra Hasan2, Rajesh Gopalarathinam3, shiri keret4, Dana Ascherman5, Siamak Mogahadam6, Chester Oddis6 and Rohit Aggarwal7, 1UPMC McKeesport, Pittsburgh, PA, 2CHI health Creighton university medical center, Omaha, NE, 3Division of Rheumatology, Wrightington Wigan and Leigh Teaching Hospitals NHS Foundation Trust, Wigan, United Kingdom, 4Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, 5Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 6Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: The 2017 ACR/EULAR classification criteria for idiopathic inflammatory myopathies (IIM) currently used in myositis clinical trials/research demonstrated 87% sensitivity and 82% specificity for a…
  • Abstract Number: 0320 • ACR Convergence 2024

    Comparative Transcriptional Profiling Reveals Shared Pathway Activation Between Human Jo-1+ Anti-Synthetase Syndrome and Murine Histidyl-tRNA Synthetase-Induced Myositis

    Iago Pinal-Fernandez1, Daniel Reay2, Timothy Oriss2, katherine Pak3, Maria Casal-Dominguez4, jose milisenda5, Albert Selva-O’Callaghan6, Werner Stenzel7, Andrew Mammen1 and Dana Ascherman8, 1NIH, Bethesda, MD, 2University of Pittsburgh School of Medicine, Pittsburgh, PA, 3National Institutes of Health, Bethesda, MD, 4NIH, Bathesda, MD, 5Hospital Clinic de Barcelona, Barcelona, Spain, 6Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, 7Charite University, Berlin, Germany, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA

    Background/Purpose: Previous work has shown unique gene expression profiles in muscle tissue corresponding to the anti-synthetase syndrome, with an emphasis on interferon gene signatures (Type…
  • Abstract Number: 0326 • ACR Convergence 2024

    Validity and Responsiveness of Core Set Measures in Idiopathic Inflammatory Myositis Based on 36-item Short Form Health Survey (SF-36)

    Maha Almackenzie1, Anushka Aggarwal2, shiri keret3, shreya Sriram4, Tanya Chandra5, Raisa Silva6, Eugenia Gkiaouraki4, Siamak Mogahadam7, Chester Oddis7 and Rohit Aggarwal8, 1Division of Rheumatology, Department of Medicine, Medical Cities of the Ministry of the Interior Riyadh, Saudi Arabia, Arlington, VA, 2Department of Rheumatology, Indraprastha Apollo Hospital, New delhi, NY, 3Rheumatology unit, Bnai-Zion medical center and the faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel., Atlit, Israel, 4Division of Rheumatology and Clinical Immunology, University of Pittsburgh Medical Center, Pittsburgh, PA, 5University of Pittsburgh Medical Center, Pittsburgh, PA, 6Internal medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, 7Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, 8Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, USA, Pittsburgh, PA

    Background/Purpose: There are six core set measures (CSMs) of disease activity in patients with idiopathic inflammatory myopathies (IIM). However, there is limited data on their…
  • Abstract Number: 1735 • ACR Convergence 2024

    High-Intensity Interval Training Outperforms Moderate Exercise in Aerobic Capacity for Recent-Onset Idiopathic Inflammatory Myopathies: A Randomized Controlled Trial

    Kristofer Andreasson1, Cecilia Leijding1, Maryam Dastmalchi2, Antonella Notarnicola3, Stefano Gastaldello1, Heléne Sandlund2, Daniel Andersson4, Ingrid Lundberg5 and Helene Alexanderson2, 1Karolinska Institutet, Stockholm, Sweden, 2Karolinska University hospital, Stockholm, Sweden, 3Karolinska University Hospital and Karolinska Institutet, Stockholm, Stockholms Lan, Sweden, 4Karolinska Institutet, Solna, Sweden, 5Karolinska Universitetssjukhuset, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Exercise is a recognized adjunctive therapy for patients with idiopathic inflammatory myopathies (IIM), enhancing physical capacity and reducing inflammation. Hitherto, moderate-to-intensive exercise has been…
  • Abstract Number: 1779 • ACR Convergence 2024

    Single-Nuclear RNA-Sequencing of Treatment Naïve JDM Muscle Highlights Dysregulated Vascular Integrity and Angiogenesis in Endothelial Cells and Decreased Nitric Oxide Synthase Signaling in Type II Muscle Fibers

    Jessica Turnier1, Chioma Madubata2, Christine Goudsmit3, Sean Ferris3, Celine Berthier3, Zilan Zheng4, Sophia Matossian3, Jeff Dvergsten5, Meredyth Wilkinson6, Lucy R Wedderburn7, Gabrielle Morgan8, Lauren Pachman9, Claudia Lalancette3, Stephen Parker3, Andrew Heaton10, J. Michelle Kahlenberg3, Gabriela K Fragiadakis2 and Jessica Neely4, 1University of Michigan, Saline, MI, 2University of California, San Francisco, San Francisco, CA, 3University of Michigan, Ann Arbor, MI, 4UCSF, San Francisco, CA, 5Duke University Hospital, Hillsborough, NC, 6Great Ormond Street Institute of Child Health, London, United Kingdom, 7UCL GOS Institute of Child Health, London, United Kingdom, 8Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, 9Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 10Cure JM, Leesburg, VA

    Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children, and it frequently follows a chronic disease course. Treatments are limited secondary…
  • 1
  • 2
  • 3
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology